VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The value of blinatumomab in ALL and future therapeutic considerations

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses treatment approaches for patients with acute lymphoblastic leukemia (ALL), highlighting the value of blinatumomab in the ALL treatment armamentarium. Dr Luskin also shares her thoughts on important questions surrounding the future use and sequencing of this agent. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter